Quinoline Antimalarials Containing a Dibemethin Group Are Active against Chloroquinone-Resistant Plasmodium falciparum and Inhibit Chloroquine Transport via the P. falciparum Chloroquine-Resistance Transporter (PfCRT)

Citations Over TimeTop 10% of 2011 papers

Abstract

A series of 4-amino-7-chloroquinolines with dibenzylmethylamine (dibemethin) side chains were shown to inhibit synthetic hemozoin formation. These compounds were equally active against cultures of chloroquine-sensitive (D10) and chloroquine-resistant (K1) Plasmodium falciparum. The most active compound had an IC(50) value comparable to that of chloroquine, and its potency was undiminished when tested in three additional chloroquine-resistant strains. The three most active compounds exhibited little or no cytotoxicity in a mammalian cell line. When tested in vivo against mouse malaria via oral administration, two of the dibemethin derivatives reduced parasitemia by over 99%, with mice treated at 100 mg/kg surviving the full length of the experiment. Three of the compounds were also shown to inhibit chloroquine transport via the parasite's chloroquine-resistance transporter (PfCRT) in a Xenopus oocyte expression system. This constitutes the first example of a dual-function antimalarial for which the ability to inhibit both hemozoin formation and PfCRT has been demonstrated directly.

Related Papers

• Chloroquine-resistant Plasmodium falciparum malaria in South Africa. A case report.(1985)
• Chloroquine-resistant Plasmodium falciparum malaria at Nchelenge, northeastern Zambia. Follow-up on 515 hospital patients.(1990)
• The in vivo and in vitro sensitivity of Plasmodium falciparum to quinine.(1985)
• → RESISTANT PLASMODIUM FALCIPARUM MALARIA CURED BY HIGH QUININE DOSAGE(1971)1 cited
• Fatal Plasmodium falciparum malaria after an inadequate response to quinine treatment.(1990)